Genetic susceptibility to radiation-induced breast cancer after Hodgkin Lymphoma

Annemieke WJ Opstal-van Winden¹, Hugoline G de Haan¹, Michael Hauptmann¹, Marjanka K Schmidt¹,², Annegien Broeke³, Nicola S Russell⁴, Cécile PM Janus⁵, Augustinus DG Krof⁶, Frederieke H van der Baan¹, Marie L De Bruin¹,², Anna M van Eggermond¹, Joe Dennis⁶, Hoda Anton Culver⁶, Christopher A Haiman¹⁰, Elinor J Sawyer¹¹, Angela Cox¹², Peter Devilee¹³,¹⁴, Maartje J Hooning¹⁵, Julian Peto¹⁶, Fergus J Couch¹⁷, Paul Pharoah¹⁸,¹⁹, Nick Orr²⁰, Douglas F Easton⁸,¹⁸, Berthe MP Aleman⁴, Louise C Strong²¹, Smita Bhatia²², Rosie Cooke²³, Leslie L Robison²⁴, Anthony J Swerdlow²³,²⁵, and Flora E van Leeuwen¹

¹Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Amsterdam, The Netherlands; ²Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; ³Division of Molecular Pathology, Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, The Netherlands; ⁴Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; ⁵Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; ⁶Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands; ⁷Copenhagen Centre for Regulatory Science (CORS), University of Copenhagen, Copenhagen, Denmark; ⁸Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; ⁹Department of Epidemiology, University of California Irvine, Irvine, California, United States of America; ¹⁰Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America; ¹¹Innovation Hub, Guy’s Cancer Centre, King’s College London, London, United Kingdom; ¹²Sheffield Cancer Research, Department of Oncology, University of Sheffield, Sheffield, United Kingdom; ¹³Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; ¹⁴Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands; ¹⁵Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; ¹⁶Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom; ¹⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America; ¹⁸Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom; ¹⁹Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; ²⁰The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom; ²¹MD Anderson Cancer Center, Houston, Texas, United States of America; ²²Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, United States of America;
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America; and Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom

**Corresponding author:**
Prof. dr Flora E. van Leeuwen, PhD
Department of Epidemiology
Head, Division of Psychosocial Research & Epidemiology
Netherlands Cancer Institute
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Phone: 31-20 512 2483 / 2480
Fax: 31-20 512 2322
E-mail: f.v.leeuwen@nki.nl

**Short title:** Role of SNPs in RT-induced breast cancer after HL

Word count (intro-discussion): 3914
Word count (abstract): 250 (max 250)
Figure/table count: 5
Reference count: 55

Primary Scientific category: Lymphoid Neoplasia
Key points

- The risk of RT-induced breast cancer after Hodgkin lymphoma is strongly associated with a PRS for breast cancer in the general population.
- A PRS, based on nine SNPs interacting with RT in the occurrence of breast cancer after HL, also increased RT-induced breast cancer risk.

Abstract

Female Hodgkin lymphoma (HL) patients treated with chest radiotherapy (RT) have a very high risk of breast cancer. The contribution of genetic factors to this risk is unclear. We therefore examined 211,155 germline single nucleotide polymorphisms (SNPs) for gene-radiation interaction on breast cancer risk in a case-only analysis including 327 breast cancer patients after chest RT for HL and 4,671 first primary breast cancer patients. Nine SNPs showed statistically significant interaction with RT on breast cancer risk (false discovery rate <20%), of which one SNP in the \( PVT1 \) oncogene attained the Bonferroni threshold for statistical significance. A polygenic risk score (PRS) composed of these SNPs (RT-interaction-PRS) and a previously published breast cancer PRS (BC-PRS) derived in the general population were evaluated in a case-control analysis comprising the 327 chest-irradiated HL patients with breast cancer and 491 chest-irradiated HL patients without breast cancer. Patients in the highest tertile of the RT-interaction-PRS had a 1.6-fold higher breast cancer risk than those in the lowest tertile. Remarkably, we observed a 4-fold increased RT-induced breast cancer risk in the highest compared with the lowest decile of the BC-PRS. On a continuous scale, breast cancer risk increased 1.4-fold per standard deviation of the BC-PRS, similar to the effect size found in the general population. This study demonstrates that genetic factors influence breast cancer risk after chest RT for HL. Given the high absolute breast cancer risk in radiation-exposed women, these results can have important implications for the management of current HL survivors and future patients.

Keywords:
Hodgkin lymphoma, radiotherapy, breast cancer, genetic susceptibility, polygenic risk score, single nucleotide polymorphisms
Introduction

Women who are treated at young ages with chest radiotherapy (RT) for Hodgkin lymphoma (HL) have a 5-20 times increased risk of breast cancer compared with the general population. The cumulative incidence of breast cancer up to 40 years after treatment with mantle field RT is 30-40%, in the range of risks observed in BRCA1/2 mutation carriers. The risk of RT-induced breast cancer rises with increasing radiation dose and volume, but not all female HL survivors treated with high-dose, high-volume RT develop breast cancer. Some variation in risk is explained by age at RT exposure, which is inversely related with breast cancer risk, and premature menopause induced by concomitant alkylating-chemotherapy treatment, which reduces risk. However, variation in risk may also be due to genetic factors. The high risk of breast cancer in this population provides an excellent opportunity to investigate the genetic basis for differential sensitivity to radiation carcinogenesis. Although it is well known that ionizing radiation induces DNA damage, the molecular mechanisms underlying radiation-induced breast carcinogenesis are unclear. To date, there is no clear evidence that known high-risk breast cancer susceptibility genes contribute to RT-induced breast cancer risk in HL patients. However, there may be a more important role for common susceptibility variants, as suggested by genetic association studies in women exposed to low-dose radiation, albeit with conflicting results. The role of single nucleotide polymorphisms (SNPs) in breast cancer risk after therapeutic high-dose radiation has been investigated in few studies: a small genome-wide association study (GWAS) on any second solid malignancy in childhood HL survivors and a GWAS on radiation-induced breast cancer in childhood cancer survivors. In addition, Ma et al. investigated 14 SNPs previously associated with breast cancer in the general population in HL survivors.

In the current study, we used a two-step design to investigate whether there are subgroups of women exposed to chest RT which are genetically more susceptible to radiation-induced breast cancer. We first used a case-only analysis to evaluate interactions between 211,155 SNPs and chest RT, by comparing patients with breast cancer after chest RT for HL with first primary breast cancer patients previously unexposed to RT. We then conducted a nested breast cancer case-control analysis among chest-irradiated HL survivors to evaluate a polygenic risk score (PRS) composed of RT-interacting SNPs from the case-only analysis (the RT-interaction-PRS). As a separate aim, we studied the effect of a previously published PRS for breast cancer in the general population (the BC-PRS) on breast cancer risk among chest-irradiated HL survivors.

Patients and methods

Study design

When studying interaction between RT and genetic variation on breast cancer after HL, a classical case-control study nested in a cohort of HL survivors would not be informative since, until recently, 90% of the
patients with breast cancer after HL received RT, resulting in too few unexposed cases. Therefore, we used a two-step design to identify susceptibility variants for radiation-induced breast cancer (Figure 1). First, we examined gene-radiation interaction for 211,155 SNPs in a case-only analysis comparing patients with breast cancer after chest RT for HL (further referred to as breast cancer after HL cases) and first primary breast cancer patients (further referred to as first primary breast cancer cases). For each SNP, we used logistic regression analysis to estimate the per-allele interaction odds ratio (IOR), a measure of departure from a multiplicative joint effect of the SNP and chest RT, for the risk of breast cancer, assuming independence between chest RT and the SNP in women from the general population.

Second, we combined interacting SNPs in a PRS, i.e. the sum of risk alleles weighted by their effect size (see Supplementary Methods A for details) and evaluated the association between this PRS and the risk of breast cancer after chest RT in a breast cancer case-control analysis among irradiated HL survivors, using an independent control group of chest-irradiated HL survivors without breast cancer as controls (further referred to as HL controls). We similarly evaluated a second PRS, which was previously reported to be associated with breast cancer in the general population (the BC-PRS).

Study population and genotyping

For the case-only analysis we pooled 339 cases with breast cancer after HL from three breast cancer case-control studies nested in HL survivor cohorts: the Childhood Cancer Survivor study (CCSS), a British HL cohort and the Dutch Hodgkin Lymphoma Cohort. Blood samples from these cases were genotyped using a custom Illumina iSelect Array comprising 211,155 SNPs, specially designed for the European Collaborative Oncological Gene-Environment Study (EU-COGS) project (referred to as iCOGS array). Extensive patient and HL treatment characteristics, as well as follow-up data were available from medical records, through questionnaires sent to general practitioners and study participants, and from record linkages with national cancer registries. Female patients with breast cancer after HL were included in our study if they were diagnosed with primary breast cancer >8 years after chest RT for HL before the age of 41 years (see Supplementary Methods B for definition of chest RT). Cases with breast cancer after HL were frequency matched (1:~14) on age and year of breast cancer diagnosis (5-year intervals) and country, to 4,673 first primary breast cancer cases of European origin not known to be exposed to chest RT. These were selected from 19,275 participants of 10 studies from the Netherlands (NL), United Kingdom (UK), and the United States of America (USA) within the Breast Cancer Association Consortium (BCAC) for whom iCOGS genotype data were available. When there were too few subjects in a specific age category, we oversampled in an adjacent age category in the same calendar year category.

For the case-control analysis, we included the 339 cases with breast cancer after HL mentioned previously and 508 HL survivors treated with chest RT who did not develop breast cancer until end of follow-up, available from the three breast cancer case-control studies described above. For all HL controls
without breast cancer, we collected similar data as described above for cases with breast cancer after HL. In the published original case-control studies\textsuperscript{13,32-34}, which examined radiation dose-response, 1-4 controls were individually matched to each case. Controls had to have survived without breast cancer at least as long as the interval between HL and breast cancer for the corresponding case, and in case of the US study, had to have donated a blood sample. In addition, controls had to match the case on age at HL treatment (±3 year) and date of HL treatment (±5 year). Controls from the original case-control studies were excluded if they were not treated with chest RT, were treated at or after age 41, and/or did not donate a blood sample. In addition, controls were excluded if they developed breast cancer after the year of breast cancer diagnosis of the case to whom they had been matched. For the current study, we added recently diagnosed breast cancer after HL cases fulfilling the inclusion criteria. All separate studies involved in this collaboration were approved by the relevant Institutional Review Boards, and all individuals gave written informed consent.

\textit{Quality control on genotype data}

After quality control, 194,106 SNPs measured in 4671 first primary breast cancer cases, 327 cases with breast cancer after HL and 491 HL controls without breast cancer remained for analyses. See Supplementary Methods C for details on quality control.

\textit{Statistical analyses}

In the case-only analysis, comparing breast cancer after HL cases and first primary breast cancer cases, we estimated the per-allele IOR by unconditional logistic regression analysis for all variants passing quality control, adjusting for the matching factors (age and year of breast cancer diagnosis, both continuous, and country) and the first principal component describing remaining genetic ethnic differences among European subjects (referred to as ethnicity) (see Supplementary Methods D). P-values for the IORs were calculated by the score test performed using the GenABEL package within R (see Supplementary Methods E). Based on a conservative Bonferroni correction, SNPs with a P-value <2.6E-07 were considered statistically significant. Furthermore, we applied the false discovery rate (FDR) by Benjamini and Hochberg\textsuperscript{37} to identify SNPs among which the expected proportion of false positives is less than 20% (q-value=0.2). For significant SNPs in linkage disequilibrium (LD; $r^2>0.7$), only the SNP with the lowest P-value was included in the PRS.

Subsequently, for all subjects in the case-control analysis (breast cancer after HL cases and HL controls) we calculated the RT-interaction-PRS consisting of SNPs interacting with RT on breast cancer at 20\% FDR and the 77-SNP BC-PRS. Missing genotypes were imputed by the mode among HL controls. Odds ratios (ORs) and corresponding 95\% confidence intervals (CIs) for RT-induced breast cancer after HL were calculated by unconditional logistic regression per standard deviation increase in either the RT-interaction-PRS and/or the BC-PRS, adjusted for each other and for age at HL diagnosis (continuous),
year of HL diagnosis (four periods), country, and ethnicity. We also calculated ORs for breast cancer by categories of the PRSSs (tertiles for the RT-interaction-PRS and deciles for the BC-PRS). P-values for the ORs were based on Wald tests. Interaction between the RT-interaction-PRS and gonadotoxic treatment for HL (yes/no) and between the RT-interaction-PRS and age at HL treatment (<20/>20 years) was tested by stratification on these factors. As a sensitivity analysis, we assessed the association of a PRS including only the SNPs attaining the Bonferroni threshold for statistical significance. For all Bonferroni-significant SNPs in the case-only analysis, we also tested their individual association with breast cancer after chest RT in the case-control analysis using logistic regression adjusted for age at and year of HL diagnosis, country, and ethnicity. All analyses were conducted with R software (http://www.r-project.org).

Data availability
Non-identifiable data that support the findings of this study will be made available upon reasonable request. Access to the BCAC data is governed by the Data Access Coordinating Committee from BCAC. Data from the CCSS study can be retrieved from dbGAP using accession number phs001327.v1.p1.

Results
Study populations of the case-only and case-control analysis
We included 327 breast cancer after HL cases from cohorts of female HL patients in NL, UK, and USA and 4,671 frequency-matched first primary breast cancer cases previously unexposed to RT from the same countries in the case-only analysis. Further, we included 491 HL controls in the case-control analysis (see Table 1 for the numbers of subjects by country). The median age at breast cancer diagnosis was 45 years (range 24-76) for breast cancer after HL cases and 46 years (range 22-84) for age-matched first primary breast cancer cases (Table 1). The median interval between HL and breast cancer diagnosis was 24 years (range 9-46). For HL controls median follow-up was 30 years (range 9-49). Most HL cases and controls (87%) were treated with mantle field irradiation, whereas 11% of the HL cases and controls received mediastinal radiotherapy without axillary node radiotherapy. About half of the breast cancer after HL cases and almost 60% of HL controls were treated for HL with chemotherapy in addition to RT. About 45% of breast cancer after HL cases and 57% of HL controls received gonadotoxic treatment (i.e., alkylating chemotherapy and/or pelvic RT).

SNPs interacting with RT on breast cancer risk (case-only analysis)
We tested 194,106 SNPs that passed quality control for an interaction with chest RT in the case-only analysis of breast cancer patients (QQ plot is depicted in Supplementary Figure 1). As shown in Table 2, three SNPs were statistically significantly associated at the Bonferroni threshold for multiple testing (P
<2.6E-07) and seven additional SNPs met the 20% FDR threshold, of which one SNP was excluded because of strong LD ($r^2$ 0.9). The estimated per-allele IORs for these nine SNPs ranged from 1.6 to 2.2. Most SNPs were quite common in the breast cancer after HL cases with minor allele frequencies (MAF) between 2.8% and 43.7%.

**Polygenic risk score for RT-induced breast cancer (case-control analysis)**

We constructed a RT-interaction-PRS of the nine SNPs that showed a statistically significant (FDR 20%) interaction with RT-induced breast cancer. The RT-interaction-PRS increased breast cancer risk after chest RT for HL with ORs of 1.2 (95% CI, 0.8-1.7; $P=0.348$) and 1.6 (95% CI, 1.1-2.4; $P=0.007$), respectively, for the middle and highest terciles compared with the lowest tercile, adjusted for age and year of HL diagnosis, country, ethnicity, and the BC-PRS (Figure 2 and Supplementary Table 1). The OR per one standard deviation (SD) of the RT-interaction-PRS was 1.3 (95% CI, 1.1-1.5; $P=0.002$).

Additional adjustment for gonadotoxic treatment did not affect the association of the RT-interaction-PRS with breast cancer risk ($OR_{adj} 1.3, 95\% CI 1.1-1.5$), suggesting that it unlikely that chemotherapy has confounded our analyses. In addition, stratified analyses resulted in similar associations between the RT-interaction-PRS and breast cancer risk among women who received gonadotoxic treatment (alkylating chemotherapy and/or pelvic RT) and women who did not; we observed no statistically significant interaction between the RT-interaction-PRS and gonadotoxic treatment ($P=0.337$; Supplementary Table 1). Likewise, stratification by age at HL treatment ($\leq 20$, >20 years) did not result in different associations between the RT-interaction-PRS and breast cancer risk after RT for HL; there was no interaction between age at HL treatment and the RT-interaction PRS ($P=0.954$).

In a sensitivity analysis, we observed that a PRS containing only the three SNPs reaching the Bonferroni threshold for statistical significance also increased breast cancer risk with ORs of 1.4 (95% CI, 1.0-2.1; $P=0.070$) and 1.6 (95% CI, 1.1-2.2; $P=0.018$), respectively, for the middle and highest terciles compared with the lowest tercile which consisted of non-carriers. The OR per one SD of the 3-SNP RT-interaction-PRS was 1.2 (95% CI, 1.0-1.4; $P=0.014$).

In order to confirm the observed associations, we also evaluated the individual effects of the three Bonferroni-significant SNPs on RT-induced breast cancer in the case-control analysis among chest-irradiated HL survivors (Supplementary Table 2). Of these, an intronic variant in oncogene PVT1 (rs10505506) was associated with RT-induced breast cancer risk after HL with an OR of 1.3 (95% CI 1.1-1.6; $P=0.007$) per allele copy. Of note, rs10505506 is not in LD ($r^2 <0.3$ in Europeans from the 1000 Genomes Project) with previously identified cancer risk variants in the PVT1 locus (Supplementary Figure 2).
Polygenic risk score based on known breast cancer SNPs (case-control analysis)

To evaluate the combined effect of known breast cancer SNPs, we studied a BC-PRS containing 76 SNPs which increase breast cancer risk in the general population\textsuperscript{30}, in chest-irradiated HL survivors. The BC-PRS was associated with a 1.4-fold increased risk of RT-induced breast cancer (95% CI, 1.2-1.6; \( P = 9.1 \times 10^{-05} \)) per standard deviation increase in the BC-PRS. The ORs for developing breast cancer after chest RT for HL by deciles of the BC-PRS, compared with women in the middle quintile (40\textsuperscript{th} to 60\textsuperscript{th} percentile), are shown in Figure 3 and Supplementary Table 3. The 10% of women with the lowest BC-PRS had an OR of 0.6 (95% CI, 0.3-1.1; \( P = 0.133 \)) for developing RT-induced breast cancer compared with women in the middle quintile, whereas the OR for the 10% of women with the highest BC-PRS was 2.4 (95% CI, 1.4-4.2; \( P = 0.002 \)), adjusted for age and year of HL diagnosis, country, ethnicity, and the RT-interaction-PRS (in tertiles). This results in a 4-fold relative risk for the 10% women with the highest compared with the lowest BC-PRS. There was no interaction between the RT-interaction-PRS and the BC-PRS (\( P = 0.645 \)).
Discussion
This study demonstrates that genetic factors influence the risk of breast cancer after chest RT for HL. We showed that a BC-PRS, consisting of 77 SNPs previously associated with breast cancer in the general population, also substantially increases the risk of breast cancer in chest-irradiated HL survivors. In addition, we identified nine SNPs interacting with chest RT and the risk of breast cancer after HL and we showed a statistically significant association of a PRS composed of these interaction SNPs with breast cancer risk after chest RT for HL using an independent control group. These results imply that the absolute risk of breast cancer due to irradiation would be (even) larger among women at high genetic risk, which is relevant for clinical risk prediction.

Importantly, we validated the previously published BC-PRS in a high-risk population of female chest-irradiated HL survivors and found that there are large differences in risk between women with a low and high PRS. More specifically, we observed a 4-fold increased relative risk between chest-irradiated HL survivors in the highest compared with the lowest decile of the BC-PRS. On a continuous scale, the effect size was very similar to that found in the general population (OR of 1.4 per SD in our study of HL survivors compared with ORs of 1.4 to 1.6 per SD in the general population)\(^{30,39}\). These results indicate that the effects of radiation exposure and common susceptibility variants, summarized in the PRS, combine approximately multiplicatively. Given the high absolute breast cancer risk in radiation-exposed women, these results have important implications for their management. The BC-PRS can be used to help guide treatment decisions in newly diagnosed HL patients as well as to help determine breast surveillance strategies for irradiated HL survivors. Annual breast cancer surveillance between the ages of 25 and 50 years is currently recommended by the International Late Effects of Childhood Cancer Guideline Harmonization Group for female survivors of childhood, adolescent, and young adult cancer who received \(\geq 20\) Gy chest radiation before age 30 years\(^{40}\). Less clear is the evidence for surveillance in women treated at older ages, with lower dosages, or with different radiation volumes. Therefore, clinical prediction models for breast cancer that include both clinical and genetic factors can help to identify (additional) women who may benefit from breast cancer surveillance.

We chose to evaluate the 77-SNP BC-PRS by Mavaddat et al.\(^{30}\), as this PRS has been associated with breast cancer risk in the general population and in high-risk groups such as BRCA1 and BRCA2 mutation carriers\(^{35,41}\), allowing direct comparison of the reported effect sizes. Nevertheless, many more common susceptibility variants have recently been identified for breast cancer in the general population\(^{42,43}\). Addition of these SNPs to the BC-PRS may further improve risk stratification for breast cancer in chest-irradiated HL survivors and in other high-risk groups. Inclusion of SNPs associated with hormone receptor-negative breast cancer may be of particular interest, as several studies have reported that HL survivors are more likely to develop hormone receptor-negative disease\(^{44-46}\).
We applied an innovative design to examine the role of SNP-radiation interactions in breast cancer risk after HL. This is not feasible in a classical breast cancer case-control study in HL survivors, as, until recently, approximately 90% of breast cancer cases after HL received chest RT. Therefore, we first performed a case-only analysis in breast cancer patients previously exposed and unexposed to chest RT, followed by a case-control analysis in HL survivors to evaluate the combined effect of the identified RT-interaction SNPs in a PRS. We used a 20% FDR as a cut-off to select SNPs interacting with RT for the RT-Interaction-PRS, as it has been shown that the performance of a PRS improves when using more liberal thresholds than the conservative Bonferroni threshold\(^{47,48}\). Although a PRS consisting of three SNPs statistically significant at the Bonferroni threshold showed a similar association with RT-induced breast cancer risk among HL survivors, the goodness-of-fit was better in the full PRS (data not shown).

The IORs which we estimated in the case-only analysis measure departure from a multiplicative joint effect of chest RT and the SNP, assuming independence between chest RT and the SNP in women from the general population\(^ {49} \). This assumption is likely to be justified except for SNPs associated with HL. SNPs associated with HL may also have shown a significant IOR in the case-only analysis. On the other hand, such SNPs may be associated with both HL and (radiation-induced) breast cancer and, therefore, we did not exclude SNPs previously associated with HL from inclusion in the RT-Interaction-PRS. If they were only associated with HL they would have attenuated the association of the RT-Interaction-PRS with breast cancer after chest-RT in the case-control analysis. In the case-only analysis, we identified one SNP (rs9461776) interacting with radiation at 20% FDR significance located in the human leukocyte antigen (HLA) region, which has extensively been reported to be associated with HL\(^ {50} \). rs9461776 showed no evidence of an association with breast cancer after chest RT (OR 1.0; 95%CI, 0.8-1.4; P>0.5) in the case-control analysis in HL survivors and may therefore have attenuated the association of the RT-Interaction-PRS with the risk of breast cancer after chest RT.

Of the nine SNPs (MAF>1%) interacting with RT on breast cancer risk at 20% FDR, one attained the genome-wide level (P<5x10^{-8}) of statistical significance. This SNP (rs10505506) was also associated with breast cancer risk in chest-irradiated HL survivors (OR 1.3; 95%CI, 1.1-1.6; P=0.007). SNP rs10505506 is located in the intronic region of **PVT1**, which is a known oncogene regulated by tumor suppressor p53 encoding a long non-coding RNA and several microRNAs\(^{51,52} \). **PVT1** has been shown to interact with the adjacent proto-oncogene **MYC** and translocations in this locus have been associated with Burkitt’s lymphoma. In addition, overexpression of **PVT1** is associated with several types of cancers including breast cancer, acute myeloid leukemia and HL. Likewise, GWAS studies have identified several conditionally independent SNPs in this locus associated with cancer, including breast cancer and HL\(^ {53,54} \), but none of these are in LD with rs10505506. A potential link with radiation has recently been suggested in a mouse model after whole-body irradiation\(^ {55} \).

The association of the RT-interaction-PRS with breast cancer risk after HL was not weakened in ‘low-risk’ groups of women irradiated at older age (i.e. 20 years or older) or women treated with gonadotoxic
treatment. In addition, we did not observe interaction between the RT-interaction-PRS and either gonadotoxic treatment or age at HL treatment. This is in line with the notion that gonadotoxic treatment and age at HL treatment are independent risk factors for breast cancer risk after HL. This suggests that age and treatment-related risk factors for breast cancer after HL and the genetic risk scores (both the RT-interaction-PRS and the BC-PRS) combine multiplicatively as has previously been shown for several reproductive risk factors and the 77-SNP BC-PRS in the general population.

A limitation of this study is that the study populations for the construction and evaluation of the RT-interaction-PRS were not independent, as the breast cancer after HL cases were included in both analyses. External validation of the RT-interaction-PRS in an independent study is therefore needed to confirm our findings. In addition, we excluded SNPs with a low MAF (<1%) from our analyses, as these low-frequency SNPs are more prone to genotyping errors. However, Morton et al., recently reported two suggestive associations for low-frequency variants at 11q23 and 1q32.3, both not present on the iCOGs array, with breast cancer risk after childhood cancer, suggesting a potential role for low-frequency SNPs in RT-induced breast cancer. Inclusion of these SNPs to the RT-interaction-PRS might strengthen its association with RT-induced breast cancer. Likewise, additional SNPs interacting with RT on breast cancer may be identified when assessing SNP data from denser genotyping chips imputed to a reference panel.

However, in this first analysis, we focused on high-quality SNPs specifically selected for the iCOGs array. In conclusion, we showed that a BC-PRS previously developed in the general population also applies in a high-risk breast cancer population of chest irradiated HL survivors. In addition, we developed a RT-interaction-PRS composed of nine SNPs interacting with radiation that was associated with raised breast cancer risk after chest RT for HL. While our RT-interaction-PRS needs validation in an independent sample, the BC-PRS can already be applied in clinical practice. This can benefit treatment-decision making in future HL patients as well as identification of high-risk survivors eligible for breast cancer surveillance.

Acknowledgements
This work was supported by a grant (2010-4720, F.E.v.L.) from the Dutch Cancer Society.

For the Dutch Hodgkin Lymphoma cohort, we would like to thank Ph.M.P. Poortmans from Elisabeth Hospital Tilburg at the time of the study, M.L.M. Lybeert from Catherina Hospital Eindhoven, G.W. Imhoff from Groningen University Medical Center, J.M.M. Raemaekers from Rijnstate Hospital/Radboud University Medical Center Nijmegen at the time of the study, J.M. Zijlstra from VU Medical Center Amsterdam, and J.H. Borger from Maastricht University Medical Center for inclusion of HL patients.

The UK Hodgkin Lymphoma cohort thanks the study participants, study staff, and clinicians who participated in the study as listed in the authorship and acknowledgements in Cooke et al. This study
was supported by Breast Cancer Now and the European Commission. The Institute of Cancer Research
acknowledges funding from the National Institute for Health Research to the Biomedical Research Centre.
The Childhood Cancer Survivor study was supported by the National Cancer Institute (CA55727, G.T.
Armstrong). Support to St. Jude Children’s Research Hospital also provided by the Cancer Center Support
(CORE) grant (CA21765, C. Roberts) and the American Lebanese-Syrian Associated Charities (ALSAC). All
sponsors of this work are public or nonprofit organizations that support science in general. They had no
role in gathering, analyzing, or interpreting the data.

Author contribution
data, and drafted the manuscript. Statistical analysis was performed by A.W.J.O.-v.W., H.G.d.H., F.v.d.B.,
and data collection. H.G.d.H., M.L.D.B., and A.M.v.E. provided administrative support and coordinated the
work. This study was supervised by M.H., M.K.S., A.B., and F.E.v.L. All authors critically revised the
manuscript.
Conflict-of-interest-disclosure: The authors declare no competing interests.
Correspondence: Flora E. van Leeuwen, Department of Epidemiology, Netherlands Cancer Institute,
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; e-mail: f.v.leeuwen@nki.nl

References
1. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG. High risk of breast
2003;21(23):4386-4394.
6. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after
49. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, Chapter 28 Genetic and Molecular Epidemiology. PA, USA: Lippincott Williams & Wilkins, PA, USA; 2008:573.
Table 1. Population characteristics of the breast cancer after Hodgkin lymphoma cases, first primary breast cancer cases and Hodgkin lymphoma controls without breast cancer.

<table>
<thead>
<tr>
<th></th>
<th>Breast cancer after Hodgkin lymphoma cases (N=327)</th>
<th>First primary breast cancer cases (N=4,671)</th>
<th>Hodgkin lymphoma controls without breast cancer (N=491)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Age at breast cancer diagnosis, y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>45 (24-76)</td>
<td>46 (22-84)</td>
<td>NA</td>
</tr>
<tr>
<td>20-29</td>
<td>8</td>
<td>2.4</td>
<td>96</td>
</tr>
<tr>
<td>30-39</td>
<td>88</td>
<td>26.9</td>
<td>855</td>
</tr>
<tr>
<td>40-49</td>
<td>139</td>
<td>42.5</td>
<td>2,224</td>
</tr>
<tr>
<td>50-59</td>
<td>68</td>
<td>20.8</td>
<td>1,129</td>
</tr>
<tr>
<td>60-69</td>
<td>20</td>
<td>6.1</td>
<td>314</td>
</tr>
<tr>
<td>70+</td>
<td>4</td>
<td>1.2</td>
<td>53</td>
</tr>
<tr>
<td>&lt;1990</td>
<td>12</td>
<td>3.7</td>
<td>226</td>
</tr>
<tr>
<td>1990-1994</td>
<td>25</td>
<td>7.6</td>
<td>606</td>
</tr>
<tr>
<td>1995-1999</td>
<td>72</td>
<td>22.0</td>
<td>1,377</td>
</tr>
<tr>
<td>2000-2004</td>
<td>86</td>
<td>26.3</td>
<td>1,329</td>
</tr>
<tr>
<td>2005-2009</td>
<td>99</td>
<td>30.3</td>
<td>1,067</td>
</tr>
<tr>
<td>2010-2014</td>
<td>33</td>
<td>10.1</td>
<td>66</td>
</tr>
<tr>
<td>Age at Hodgkin lymphoma diagnosis, y</td>
<td>19 (10-40)</td>
<td></td>
<td>22 (6-40)</td>
</tr>
<tr>
<td>&lt;15</td>
<td>40</td>
<td>12.2</td>
<td>NA</td>
</tr>
<tr>
<td>15-19</td>
<td>134</td>
<td>41.0</td>
<td>NA</td>
</tr>
<tr>
<td>20-24</td>
<td>76</td>
<td>23.2</td>
<td>NA</td>
</tr>
<tr>
<td>25-29</td>
<td>38</td>
<td>11.6</td>
<td>NA</td>
</tr>
<tr>
<td>30-34</td>
<td>31</td>
<td>9.5</td>
<td>NA</td>
</tr>
<tr>
<td>35-40</td>
<td>8</td>
<td>2.4</td>
<td>NA</td>
</tr>
<tr>
<td>Year of Hodgkin lymphoma diagnosis†</td>
<td>92</td>
<td>28.1</td>
<td>NA</td>
</tr>
<tr>
<td>1965-1973</td>
<td>120</td>
<td>36.7</td>
<td>NA</td>
</tr>
<tr>
<td>1974-1979</td>
<td>60</td>
<td>18.3</td>
<td>NA</td>
</tr>
<tr>
<td>Interval between Hodgkin lymphoma and breast cancer diagnosis (cases) or end of follow-up (controls), y</td>
<td>24 (9-46)</td>
<td>NA</td>
<td>30 (9-49)</td>
</tr>
<tr>
<td>9-&lt;15</td>
<td>28</td>
<td>8.6</td>
<td>NA</td>
</tr>
<tr>
<td>≥15-&lt;25</td>
<td>144</td>
<td>44.0</td>
<td>NA</td>
</tr>
<tr>
<td>≥25-&lt;35</td>
<td>127</td>
<td>38.8</td>
<td>NA</td>
</tr>
<tr>
<td>≥35</td>
<td>28</td>
<td>8.6</td>
<td>NA</td>
</tr>
</tbody>
</table>
Genetic susceptibility to radiation-induced breast cancer

<table>
<thead>
<tr>
<th>Hodgkin lymphoma treatment</th>
<th>160</th>
<th>48.9</th>
<th>NA</th>
<th>201</th>
<th>40.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiotherapy only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiotherapy and chemotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiotherapy; chemotherapy missing</td>
<td>7</td>
<td>2.1</td>
<td>NA</td>
<td>6</td>
<td>1.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mantle field irradiation</th>
<th>234</th>
<th>90.7</th>
<th>NA</th>
<th>371</th>
<th>84.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>160</td>
<td>48.9</td>
<td>NA</td>
<td>284</td>
<td>57.8</td>
</tr>
<tr>
<td>No</td>
<td>18</td>
<td>7.0</td>
<td>NA</td>
<td>60</td>
<td>13.7</td>
</tr>
<tr>
<td>Missing</td>
<td>6</td>
<td>2.3</td>
<td>NA</td>
<td>6</td>
<td>1.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pelvic radiotherapy</th>
<th>39</th>
<th>11.9</th>
<th>NA</th>
<th>59</th>
<th>12.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>288</td>
<td>88.1</td>
<td>NA</td>
<td>432</td>
<td>88.0</td>
</tr>
<tr>
<td>No</td>
<td>288</td>
<td>88.1</td>
<td>NA</td>
<td>432</td>
<td>88.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Alkylating chemotherapy</th>
<th>133</th>
<th>40.7</th>
<th>NA</th>
<th>253</th>
<th>51.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>176</td>
<td>53.8</td>
<td>NA</td>
<td>211</td>
<td>43.0</td>
</tr>
<tr>
<td>No</td>
<td>18</td>
<td>5.5</td>
<td>NA</td>
<td>27</td>
<td>5.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gonadotoxic treatment</th>
<th>152</th>
<th>46.5</th>
<th>NA</th>
<th>278</th>
<th>56.6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkylating chemotherapy and/or pelvic radiotherapy</td>
<td>152</td>
<td>46.5</td>
<td>NA</td>
<td>278</td>
<td>56.6</td>
</tr>
<tr>
<td>No alkylating chemotherapy and no pelvic radiotherapy</td>
<td>158</td>
<td>48.3</td>
<td>NA</td>
<td>192</td>
<td>39.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Country</th>
<th>Country</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Netherlands</td>
<td>112</td>
<td>34.3</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>146</td>
<td>44.6</td>
</tr>
<tr>
<td>United States of America</td>
<td>69</td>
<td>21.1</td>
</tr>
</tbody>
</table>

IQR indicates interquartile range

* Four cases with breast cancer after Hodgkin lymphoma had missing year of breast cancer diagnosis, which were imputed with the median year of breast cancer diagnosis among participants from the same country.

† Four cases with breast cancer after Hodgkin lymphoma and six Hodgkin lymphoma controls had missing year of Hodgkin lymphoma diagnosis. These missing years were imputed with the median year of Hodgkin lymphoma diagnosis among participants in the same group (cases or controls) from the same country.

‡ For the Dutch Hodgkin lymphoma survivors, chest RT was defined as (in)complete mantle field or mediastinal RT, or RT to the lungs or axilla. Subjects with only infradiaphragmatic RT were excluded. For Hodgkin lymphoma survivors from the USA, chest RT was defined as chest or total nodal RT (subjects with only brain, other head, neck, abdomen, spine, pelvis and/or limb RT were excluded). For Hodgkin lymphoma survivors from the UK, chest RT was defined as mantle field, chest, mediastinal, axillary, mini mantle field or partial chest RT (subjects with only neck, clavicular and/or head or other supradiaphragmatic RT or infradiaphragmatic RT, RT field unknown or chemotherapy only were excluded).

§ Information on the radiation fields was only available for HL survivors from the UK and The Netherlands.

|| Pelvic RT encompassed RT to the whole abdomen or iliac nodes on both sides, or RT with inverted Y field, in women with no (successful) oophoropexy.

¶ Alkylating chemotherapy consists of combinations of cytostatic agents with at least one alkylating agent (i.e. procarbazine, cyclophosphamide, ifosfamide, lomustine, melphalan, dacarbazine, cisplatin, mechlorethamine, chlorambucil, and carmustine).
Table 2. Characteristics of SNPs statistically significantly (20% FDR) interacting with RT in the case-only analysis

<table>
<thead>
<tr>
<th>SNP</th>
<th>Locus</th>
<th>Chr</th>
<th>Position†</th>
<th>Alleles</th>
<th>MAF</th>
<th>N called</th>
<th>MAF</th>
<th>N called</th>
<th>IOR</th>
<th>95% CI</th>
<th>P‡</th>
<th>Log IOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs10505506</td>
<td>PVT1</td>
<td>8</td>
<td>129114473</td>
<td>G/C</td>
<td>0.407</td>
<td>327</td>
<td>0.306</td>
<td>4670</td>
<td>1.6</td>
<td>1.3 - 1.8</td>
<td>3.1E-08</td>
<td>0.44</td>
</tr>
<tr>
<td>rs12086369</td>
<td>1p31.1</td>
<td>1</td>
<td>79644149</td>
<td>G/A</td>
<td>0.073</td>
<td>324</td>
<td>0.035</td>
<td>4667</td>
<td>2.1</td>
<td>1.5 - 2.8</td>
<td>9.4E-08</td>
<td>0.74</td>
</tr>
<tr>
<td>rs9461776</td>
<td>HLA</td>
<td>6</td>
<td>32683713</td>
<td>A/G</td>
<td>0.133</td>
<td>327</td>
<td>0.079</td>
<td>4671</td>
<td>1.8</td>
<td>1.4 - 2.3</td>
<td>1.1E-07</td>
<td>0.59</td>
</tr>
<tr>
<td>MitoA7769G</td>
<td></td>
<td>MT</td>
<td>7769</td>
<td>A/G</td>
<td>0.052</td>
<td>325</td>
<td>0.020</td>
<td>4653</td>
<td>2.1</td>
<td>1.5 - 3.0</td>
<td>2.8E-06</td>
<td>0.76</td>
</tr>
<tr>
<td>rs1017639</td>
<td>CPT1A</td>
<td>11</td>
<td>68355110</td>
<td>A/C</td>
<td>0.073</td>
<td>327</td>
<td>0.043</td>
<td>4669</td>
<td>1.9</td>
<td>1.4 - 2.6</td>
<td>2.8E-06</td>
<td>0.63</td>
</tr>
<tr>
<td>MitoT9900C</td>
<td></td>
<td>MT</td>
<td>9900</td>
<td>A/G</td>
<td>0.028</td>
<td>325</td>
<td>0.011</td>
<td>4669</td>
<td>2.0</td>
<td>1.3 - 3.2</td>
<td>3.7E-06</td>
<td>0.71</td>
</tr>
<tr>
<td>MitoA13781G</td>
<td></td>
<td>MT</td>
<td>13781</td>
<td>A/G</td>
<td>0.036</td>
<td>306</td>
<td>0.011</td>
<td>4592</td>
<td>2.2</td>
<td>1.5 - 3.3</td>
<td>4.3E-06</td>
<td>0.80</td>
</tr>
<tr>
<td>rs2296008</td>
<td>COL19A1</td>
<td>6</td>
<td>70935424</td>
<td>G/A</td>
<td>0.041</td>
<td>327</td>
<td>0.020</td>
<td>4669</td>
<td>2.2</td>
<td>1.4 - 3.4</td>
<td>6.8E-06</td>
<td>0.79</td>
</tr>
<tr>
<td>rs815871</td>
<td>PVT1</td>
<td>8</td>
<td>129077760</td>
<td>G/C</td>
<td>0.437</td>
<td>327</td>
<td>0.341</td>
<td>4671</td>
<td>1.5</td>
<td>1.3 - 1.8</td>
<td>8.5E-06</td>
<td>0.40</td>
</tr>
</tbody>
</table>

Chr indicates chromosome; CI, confidence interval; FDR, false discovery rate; IOR, interaction odds ratio; MAF, minor allele frequency; MT, mitochondrial DNA; PRS, polygenic risk score; RT, radiotherapy; and SNP, single nucleotide polymorphism.

* Logistic regression analysis per SNP to test the log additive effect per allele (per-allele IOR) with adjustment for age at and year of breast cancer diagnosis, country, and ethnicity.
† Positions are based on NCBI36/hg18.
‡ All listed SNPs were significant at a 20% FDR. Top three SNPs were statistically significant at the Bonferroni threshold (P < 2.6E-07).
Figure 1. Study design

Figure 2. Risk of breast cancer after chest RT by tertiles of the RT-interaction-PRS among HL survivors

Figure 3. Risk of breast cancer after chest RT by deciles of the BC-PRS in the breast cancer after Hodgkin lymphoma case-control analysis
1st step: Case-only study
- Test 194,106 SNPs for statistical interaction with RT among:
  - RT for HL
  - BC
  - 327 BC after HL cases
  - BC
  - 4671 1st primary BC cases

year & age →

- Obtain IOR (Interaction Odds Ratio) per SNP
- Select most significant SNPs for validation in 2nd step

2nd step: Case-Control study
- Calculate Polygenic Risk Score (risk-weighted sum) of:
  - SNPs significantly interacting with RT (RT-interaction-PRS)
  - 77 SNPs associated with BC in general population* (BC-PRS)
- Test association of both PRSs with BC after HL among:
  - RT for HL
  - BC
  - 327 BC after HL cases
  - RT for HL
  - No BC
  - 491 HL controls

* Mavaddat et al JNCI 2015
Figure 2

For trend = 0.002

P = 0.348

P = 0.007

OR (95% CI)

Breast cancer after Hodgkin lymphoma cases, n(%)

<table>
<thead>
<tr>
<th></th>
<th>Low 9-SNP RT-interaction-PRS</th>
<th>Medium 9-SNP RT-interaction-PRS</th>
<th>High 9-SNP RT-interaction-PRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>n(%)</td>
<td>94 (28.7)</td>
<td>105 (32.1)</td>
<td>128 (39.1)</td>
</tr>
</tbody>
</table>

Hodgkin lymphoma controls without breast cancer, n(%)

<table>
<thead>
<tr>
<th></th>
<th>Low 9-SNP RT-interaction-PRS</th>
<th>Medium 9-SNP RT-interaction-PRS</th>
<th>High 9-SNP RT-interaction-PRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>n(%)</td>
<td>168 (34.2)</td>
<td>176 (35.8)</td>
<td>147 (29.9)</td>
</tr>
</tbody>
</table>
Genetic susceptibility to radiation-induced breast cancer after Hodgkin Lymphoma